ADMA BIOLOGICS INC (ADMA)

US0008991046 - Common Stock

3.54  -0.05 (-1.39%)

After market: 3.58 +0.04 (+1.13%)

ADMA BIOLOGICS INC

NASDAQ:ADMA (9/28/2023, 7:00:00 PM)

After market: 3.58 +0.04 (+1.13%)

3.54

-0.05 (-1.39%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-09 2023-08-09/amc
Earnings (Next)11-07 2023-11-07/amc
Ins Owners1.79%
Inst Owners74.42%
Market Cap796.17M
Shares224.91M
PEN/A
Fwd PE29.54
Dividend YieldN/A
Analysts84
IPO10-17 2013-10-17
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ADMA Daily chart

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 617 full-time employees. The company went IPO on 2013-10-17. The company develops, manufactures, and markets specialty plasma-derived biologics for the treatment and prevention of infectious diseases. The company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product includes BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates over 10 source plasma collection facilities in the United States. Its Plasma Collection Centers segment provides a portion of its blood plasma for the manufacture of its products.

Company Info

ADMA BIOLOGICS INC

C/O Adma Biologics, Inc., 465 State Route 17

Ramsey NEW JERSEY 07446

P: 12014785552.0

CEO: Adam S. Grossman

Employees: 617

Website: https://www.admabiologics.com/

ADMA News

News Image13 days ago - Market News VideoCommit To Buy ADMA Biologics At $2.50, Earn 8.9% Annualized Using Options
News Image2 months ago - The Motley FoolWhy Shares of ADMA Biologics Are Climbing Thursday

The company, which focuses on infectious diseases, reported its second-quarter earnings on Wednesday after the markets closed.

News Image2 months ago - Seeking AlphaADMA Biologics GAAP EPS of -$0.03 in-line, revenue of $60.13M beats by $4.63M (NASDAQ:ADMA)

ADMA Biologics press release (ADMA): Q2 GAAP EPS of -$0.03 in-line.Revenue of $60.13M (+77.4% Y/Y) beats by $4.63M.FY2024 and 2025 Total Revenue Guidance Increased to $275...

News Image2 months ago - ADMA Biologics, Inc.ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
News Image2 months ago - ADMA Biologics, Inc.ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net...

News Image2 months ago - ADMA Biologics, Inc.ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ET

ADMA Twits

Here you can normally see the latest stock twits on ADMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example